JAMA Network
About The Study: In this study of people taking pre-exposure prophylaxis (PrEP) for HIV, tenofovir alafenamide fumarate (TAF) use was found to be associated with higher incident hypertension and statin initiation compared with tenofovir disoproxil fumarate use, especially in those 40 years or older. Continued monitoring of blood pressure and lipids for TAF users is warranted.
Authors: Adovich S. Rivera, M.D., Ph.D., of Kaiser Permanente Southern California in Pasadena, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2023.32968)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
